110 related articles for article (PubMed ID: 28323753)
1. Budget impact of antiretroviral therapy in a French clinic cohort.
Papot E; Landman R; Louni F; Charpentier C; Peytavin G; Certain A; Fradet C; Castro DR; Preau M; Goujard C; Yeni P; Yazdanpanah Y;
AIDS; 2017 Jun; 31(9):1271-1279. PubMed ID: 28323753
[TBL] [Abstract][Full Text] [Related]
2. Desimplification of Single Tablet Antiretroviral (ART) Regimens-A Practical Cost-Savings Strategy?
Krentz H; Campbell S; Gill J
J Int Assoc Provid AIDS Care; 2019; 18():2325958218822304. PubMed ID: 30672364
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa.
Ciaffi L; Koulla-Shiro S; Sawadogo A; le Moing V; Eymard-Duvernay S; Izard S; Kouanfack C; Ngom Gueye NF; Fobang AA; Reynes J; Calmy A; Delaporte E;
AIDS; 2015 Jul; 29(12):1473-81. PubMed ID: 26244387
[TBL] [Abstract][Full Text] [Related]
4. Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines.
Treskova M; Kuhlmann A; Bogner J; Hower M; Heiken H; Stellbrink HJ; Mahlich J; Schulenburg JM; Stoll M
Medicine (Baltimore); 2016 Jun; 95(26):e3961. PubMed ID: 27367993
[TBL] [Abstract][Full Text] [Related]
5. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
6. The clinical role and cost-effectiveness of long-acting antiretroviral therapy.
Ross EL; Weinstein MC; Schackman BR; Sax PE; Paltiel AD; Walensky RP; Freedberg KA; Losina E
Clin Infect Dis; 2015 Apr; 60(7):1102-10. PubMed ID: 25583979
[TBL] [Abstract][Full Text] [Related]
7. [Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
Kuhlmann A; Mittendorf T; Hower M; Heiken H; Gerschmann S; Klauke S; Lutz T; Bogner J; Degen O; van Lunzen J; Bachmann C; Stellbrink HJ; Schmidt W; Leistner I; Mahlich J; Ranneberg B; Stoll M
Gesundheitswesen; 2015 Jun; 77(6):e133-42. PubMed ID: 25247761
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
10. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
11. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
12. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Ahmed BS; Phelps BR; Reuben EB; Ferris RE
Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
[TBL] [Abstract][Full Text] [Related]
13. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
14. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.
Angeletti C; Pezzotti P; Antinori A; Mammone A; Navarra A; Orchi N; Lorenzini P; Mecozzi A; Ammassari A; Murachelli S; Ippolito G; Girardi E
HIV Med; 2014 Mar; 15(3):165-74. PubMed ID: 24495188
[TBL] [Abstract][Full Text] [Related]
16. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
[TBL] [Abstract][Full Text] [Related]
18. Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
Krentz HB; Campbell S; Gill VC; Gill MJ
HIV Med; 2018 Apr; 19(4):290-298. PubMed ID: 29368401
[TBL] [Abstract][Full Text] [Related]
19. Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.
Desmonde S; Eboua FT; Malateste K; Dicko F; Ekouévi DK; Ngbeché S; Koueta F; Sy HS; Renner L; Koumakpai SA; Leroy V;
AIDS; 2015 Jul; 29(12):1527-36. PubMed ID: 26244392
[TBL] [Abstract][Full Text] [Related]
20. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
